Defeating solid tumors
with potent living medicines

Bio4t2 develops Chimeric Antigen Receptor T cell (CAR-T) therapies to treat patients with solid tumors.

Our Vision

Treat all solid tumors with personalized living medicines.
No recurrence.

Our Science

Solid tumors like lung, colorectal and pancreatic cancers are exceptionally challenging to treat.  They are multifaceted and ever-changing, and establish a tumor microenvironment (TME) that has evaded effective therapy… until now.

With PrismCoreᵀᴹ, Bio4t2 develops innovative CAR-T therapies that overcome solid tumor impediments to treatment.  Our therapies are designed to be highly selective for their on-tumor targets, potent in killing response to tumor cells, and persistent within patients towards achieving a complete response and establishing an immunological memory to mitigate future recurrence. 

Each Bio4t2 CAR-T therapy is developed with differentiated antibody binders and a de novo CAR structure that is fine-tuned to optimize the therapeutic effect on the selected target(s).

We are developing both single-target CAR-T therapies and Multi-Valent CAR-Tᵀᴹ therapies that target several tumor antigens and include other therapeutic modalities (for example, checkpoint inhibition), to deliver a combination of therapies through T cells.  Our first Multi-Valent CAR-T, a bi-targeting therapy, is a critical advancement towards addressing tumor heterogeneity and antigen loss to comprehensively treat solid tumors.  Multi-Valent CAR-Ts will enable Bio4t2 to  realize our vision of prevent all forms of recurrence.


PrismCore is Bio4t2’s tech-enabled engine for the discovery and development of CAR-T therapies for solid tumors. It combines Antibody Discovery, Therapy Design and Directive Selection with computational capabilities to create de novo CAR-T therapies that are fine-tuned specifically for their targets. PrismCore develops “clinic ready” CAR-T therapies in an accelerated timeframe – within 4 – 6 months upon selecting the tumor target(s).

Every aspect of PrismCore simulates the treatment of our patients including the exclusive use of primary human T cells, highly correlative animal models and clinically relevant processes. Our CAR-Ts are optimized to treat patients with a high degree of safety, efficacy and durability for a long-lasting response.

Our Pipeline

bio4t2 program pipeline graphic

Bio4t2 announces first patient infused with CAR-T targeting solid tumors

Our Team


Laurence is a board certified in pediatric hematology and oncology, was CEO from 2015 to 2021of Ziopharm Oncology a publicly traded company. Prior to industry, Laurence was a tenured professor at MD Anderson Cancer Center where he was chief of the pediatric bone marrow transplantation and helped lead scientific and clinical efforts to develop and implement new treatment approaches in numerous trials which paired genetic engineering with immunotherapies. Among his multiple contributions, his work in T-cell therapy includes rapid “next day” manufacture of CAR-T, combining IL-15 with CAR biology, and redirecting T-cell specificity to neoantigens to target solid tumors. He has started numerous companies and seed investor inside biotechnology (Secure Transfusion SolutionsCellChorusAuraVax Therapeutics) and outside the field (Ignite PowerChalice Wealth Partners). He is on several Boards including Bio4t2. (Links:

Farzad has more than 20 years of experience in life sciences and biotech industries with a strong focus on cellular therapy and immuno-oncology products including CAR-T, allogeneic CAR-T, allogeneic ‘off the shelf’ stem cell/iPSC-based therapeutics, mammalian genome editing and synthetic biology. He also held multiple senior leadership R&D roles in several pharma/biotech companies such as Intrexon, Synthetic Genomics, Life Technologies Corporation (Thermifisher Scientific) and Codexis Inc., where he initiated and directed multiple cutting-edge adaptive cell therapy (engineering T cells, T cell receptors (TCRs), NK cells) and therapeutics discovery platforms, xenotransplantation, protein engineering and industrial enzymes evolution programs. He is also experienced in bio-manufacturing and product development.

Farzad holds a PhD and a postdoctoral fellowship in Molecular, Cellular & Systems Biology from the University of Melbourne, Australia, and a postdoctoral fellowship from Stanford University, California.

Helena (Liqun) Jiang brings nearly 20 years of industry R & D and management experience in drug discovery programs to Bio4t2. Her vast experience includes target validation, assay development and validation, for various target families and disease areas. Helena is responsible for managing Bio4t2 operations in China.

She has managed hundreds of projects for pharmaceutical/biotech companies in the US, Europe and China resulting in value-added contributions to their pipelines while working for leading companies including Adlai Nortye, BioDuro and HD Biosciences.

Helena’s education includes a Master of Science in Cellular and Molecular in biology from Peking Union Medical College, graduate school work and Research Associate with University of Texas at Austin, and an Executive MBA from University of Plymouth.

Board Members

Dr. Masood Tayebi is a Founding Partner and the CEO of the Bridgewest Group. He has a wealth of experience commercializing new technology, particularly in pharmaceutical and biotechnology sectors, as well as the wireless communications sectors. Dr Tayebi is directly responsible for managing Bridgewest investments in biotechnology and pharmaceuticals, hi-tech and wireless technologies, and software.

He has successfully founded many companies, including a global wireless communications service company, a disruptive semiconductor IP technology company, and BioDuro, a Global CRO company with over 1,000 employees with operations in the USA and China. Dr. Tayebi has been integral in the success of multiple public and private companies alongside his brother, Dr. Massih Tayebi.

Cyrus Mirsaidi is the current chairman and managing partner of BioSelective Capital Investments, a Utah-based risk-capital biotech investment company with focus on early stage therapeutics and select translational opportunities.  He is co-founder of BioArdis and a member of its Board of Directors.

In addition, Mr. Mirsaidi is an executive committee member and operating partner at Bridgewest Ventures, New Zealand, serves in Advisory roles with Advent International, and is on the Board of BioDuro-Sundia, a contract research, development and manufacturing company, where he served as President and CEO from 2015 to 2021.  Prior to BioDuro-Sundia, Mr. Mirsaidi served as CEO of Formex, was the founder and CEO of Molecular Response, and served in key executive roles at AltheaDx, Ontogen, Inc. and Quest Diagnostics.

Mr. Mirsaidi received a BS in Biology from University of California, Irvine.  Mr. Mirsaidi resides in Deer Valley, Utah, and relishes in sharing the wines he makes in his spare time with family and friends.

Scientific & Clinical Advisors

Professor, Chair, Gene-Immunotherapy; Director of Center for Interventional Immunology (RCI), University of Regensburg

Dr. Hinrich Abken is a Professor at the University of Regensburg and holds the Chair for Genetic Immunotherapy.  He is also the Director of Center for Interventional Immunology (RCI) where he focuses on the development of adoptive cell therapy of malignant diseases using engineered T cells.  Dr. Abken studied medicine at Essen University, completed his doctoral thesis at the Institute for Molecular Biology, and performed his post-doctorate research at the Institute for Cell Biology (Professor Rajewsky).  He received his venia legendi in Genetics and Immunology from the Faculty of Science of the Rheinische Wilhelms Universität Bonn where he was group leader at the Institute for Genetics. In 1993, he became C3 University Professor for Tumor Genetics at the Medical Faculty of the University of Cologne and was member of the CMMC with an Independent Research Group. In June 2018, Dr. Abken joined the RCI and the University Regensburg.  Dr. Abken’s current research is aimed at improving T cell targeting of cancer, at developing novel strategies in modulating an immune response and at translating the T cell strategy into clinical trials.

Deputy Chief, Thoracic Service; Co-Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York

Dr. Adusumilli is a world-renowned thoracic surgeon with expertise in the diagnosis and treatment of cancers in the chest — lung cancer, esophageal cancer, mesothelioma, thymoma, mediastinal and chest wall tumors, and cancers metastatic to lung and pleura.

Professor of Medicine, Vice Chief, Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine, University of Pennsylvania

Dr. Steven M. Albelda currently serves as Vice Chief and Director of Lung Research, Pulmonary and Critical Care Medicine at the Harron Lung Center, Perelman Center for Advanced Medicine – a facility of the Hospital of the University of Pennsylvania. He is also currently a William Maul Measey Professor of Medicine at the Perelman School of Medicine. Dr. Albelda graduated from Williams College and received his medical degree from the University of Pennsylvania School of Medicine. Dr. Albelda performed his post-graduate studies at Penn Medicine.

Dr. Albelda is the recipient of the Physician-Scientist Award from the Lung Division of the National Institutes of Health and the 2010 Wagner Medal from the Mesothelioma Interest Group. Dr. Albelda is published in nearly 140 peer-reviewed journals and papers.  He has also contributed to a number of research journals and book chapters.


©2019-2022 All rights reserved. Bio4t2™ and PrismCore™ are trademarks of Bio4t2.


News Article 1


Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.